I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
The aim is to facilitate access for the French research community to the services from the unique national infrastructure and scientific expertise of the PHENOMIN’s partners, and to deliver novel mouse lines that providing important opportunities to advance knowledge gene function in relation to human development and disease. The calls are opened to French research applicants. The project will be submitted to a review process by an external scientific committee based on the scientific evaluation of their project according to the following criteria:
Request services are done on line through the internet common platform from the PHENOMIN website. Each applicant will be informed of the outcome of the evaluation within the timing that has been defined for each call. For the calls that are non-free of charge, the cost of the project will be given to the selected applicant for placing an official order.
Do you want to be kept informed of the next PHENOMIN calls ? We invite you to subscribe to our newsletter.
The project must be based on scientifically validated preliminary data and the choice of the experimental model must be clearly justified. The call is dedicated only to generating new experimental models for rare diseases i) animal models, ii) in vitro models based on induced pluripotent stem cell (iPSC) (including conditions for archiving lines).
Any other request (breeding, phenotyping, advanced imaging etc.) is not eligible.
Only one project per research team can be funded.
To develop the new experimental animal models of rare diseases, successful applicants will have a facilitated access to experimented platforms for which most of them are being part of CELPHEDIA, the French infrastructure that promotes innovative services and tool on model organisms:
The precise type of model development (knock-out, knock-in, humanized model, transgenic…), will be specific to each organism, but will rely on the latest improvements and most appropriate techniques of genome editing (ZFNs, TALEN, CRISPR/CAS9, etc.) or more classical transgenic approaches (such as DNA microinjection or lentiviral infection).
For animal models, if specific needs are not covered by partner platforms, please contact the Foundation at email@example.com in order to evaluate eligibility of the proposed model and conditions of services. In any case, technical issues must have been discussed with platforms to ensure feasibility of the project. The model will be developed with the support of a platform.
For the development of in vitro models based on induced pluripotent stem cell (iPSC) lines, the best suited approach will be designed for each project. Please pay attention that only projects for which agreements of lineage derivation from iPS of patients have already been obtained will be considered. Human induced pluripotent stem cell (iPSC) lines will be developed with the support of the Platform iPSC Nantes.
This Trans-national Access call of the INFRAFRONTIER2020 project supports a total of 3 precision rat model development projects. A complementary call provides support for 12 customised mouse model development projects.
9 new additional CreERT2 mouse lines are generating by PHENOMIN team and will be made available as soon as possible for the scientific community and 4 CreERT2 mouse models have been already generated by the European EUCOMMTOOLS consortium and and will be further characterized.
The French Foundation for rare diseases "Fondation maladies rares" and the French National Infrastructure PHENOMIN launched 3 successive joint calls "Mouse models and rare diseases" (in 2017, 2015 and 2013, respectively) to give a significant boost to the development of mouse models, in order to i) gain a better understanding of the pathophysiological mechanisms involved in rare diseases whose defective genes have been identified, ii) Test and validate therapeutic proofs of concept, at the pre-clinical in vivo level. 45 projects and then new mouse models have been or are being realized from 129 submissions.
2013: Expressions of Interest for generation of transgenic mouse lines bearing a single gene knock-out (with conditional potential) in order to establish and characterize conditional Knock-Out (cKO) models. 45 additional new mouse lines have been generated by PHENOMIN, in order to be available as soon as possible for the scientific community.